Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Heart Failure with preserved Ejection Fraction (HFpEF) is defined by clinical symptoms of dyspnea and fatigue~* Normal left ventricular ejection fraction (\>/=50%)~* And elevated Left Ventricular (LV) filling pressure at cardiac catheterization (defined as resting Pulmonary Capillary Wedge Pressure (PCWP)\>15 mmHg and/or PCWP \>/=25 mmHg during exercise).~Exclusion Criteria:~* Systolic Blood Pressure \<120 mmHg (during catheterization)~* Prior nitrate therapy (within previous 2 weeks)~* Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency~* Other non-HFpEF specific causes of heart failure such as significant valvular disease (\>moderate left-sided regurgitation, \>mild stenosis)~* Severe pulmonary disease~* Unstable coronary disease or coronary spasm~* Primary renal or hepatic disease (end stage renal failure/on dialysis or clinical diagnosis of hepatitis or hepatic cirrhosis)~* Constrictive pericarditis, or infiltrative, restrictive, or hypertrophic cardiomyopathies~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Saline) (Type: PLACEBO_COMPARATOR): Participants receive normal saline, administered by inhalation over 10-15 minutes, using a nebulizer
- Sodium Nitrite (Type: EXPERIMENTAL): Participants receive Sodium Nitrite inhalation solution, administered by inhalation over 10-15 minutes, using a nebulizer

Based on this trial design, predict the completion outcome and termination type (if applicable).